SCHEMBL4211248

SCHEMBL4211248

CCCCOc1cc(C=C(C)C(=O)O)ccc1-c1cccc(CNC)c1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.43
KDM4E B2RXH2 3/20 0.41
PTPN11 Q06124 5/20 0.41
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
FFAR1 O14842 2/20 0.39
AKR1C3 P42330 1/20 0.38
ALOX5 P09917 2/20 0.37
PTGES O14684 1/20 0.37
PPARG P37231 1/20 0.37
CNR2 P34972 1/20 0.36
PLA2G4A P47712 2/20 0.36
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
PGGT1B P53609 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4211240 1.00 HTR7 (0.43) HTR7KDM4EPTPN11ALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL4216956 0.95 KDM4E (0.40) HTR7KDM4EPTPN11ALDH1A1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL4216969 0.95 KDM4E (0.40) HTR7KDM4EPTPN11ALDH1A1SMN1; SMN2
SCHEMBL4217552 0.89 HTR7 (0.42) HTR7KDM4EPTPN11ALDH1A1SMN1; SMN2
SCHEMBL4209272 0.86 KDM4E (0.41) KDM4EPTPN11ALDH1A1SMN1; SMN2FFAR1
SCHEMBL4219792 0.86 KDM4E (0.41) KDM4EPTPN11ALDH1A1SMN1; SMN2FFAR1
SCHEMBL2085390 0.86 KDM4E (0.43) KDM4EPTPN11ALDH1A1SMN1; SMN2ALOX5
SCHEMBL2085387 0.86 KDM4E (0.43) KDM4EPTPN11ALDH1A1SMN1; SMN2ALOX5
SCHEMBL4213888 0.86 KDM4E (0.43) KDM4EPTPN11ALDH1A1SMN1; SMN2ALOX5
SCHEMBL4216964 0.86 HTR7 (0.38) HTR7KDM4EPTPN11FFAR1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed
EP-1943213-A2 PPAR MODULATING BIAROMATIC COMPOUNDS Galderma Research & Development (FR) 2008-07-16 EP disclosed
WO-2007049158-A2 PPAR MODULATING BIAROMATIC COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA HTR7 878/4885KDM4E 2728/4885PTPN11 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.